CapsoVision Reports 17% Revenue Growth to $3.3 Million in Q2 2025

CapsoVision, Inc. reported its financial results for the second quarter of 2025, revealing a net revenue of $3.3 million, a 17% increase from $2.8 million in the same period last year. For the first half of 2025, the company generated $6.1 million in revenue, up 14% from $5.3 million in the prior year. The growth in revenue was primarily driven by an increase in sales of the CapsoCam Plus capsules, which saw a 17% rise in unit sales for the quarter. However, the company continues to face challenges, with a net loss of $4.6 million for the quarter, slightly improved from a loss of $5.3 million in Q2 2024.

In terms of operational metrics, CapsoVision's costs of revenue increased by 20% to $1.5 million for the second quarter, reflecting the higher sales volume. The gross profit for the quarter was $1.8 million, resulting in a gross margin of 55%, down from 56% in the previous year. The company’s total operating expenses decreased by 6% to $6.5 million, with notable reductions in research and development costs, which fell by 20% to $3.4 million, attributed to the completion of the CapsoCam Colon pivotal study.

CapsoVision has made strategic moves to enhance its product offerings and market presence. The company is developing the CapsoCam Colon capsule, which is expected to receive FDA clearance in early 2026. Additionally, the company has recently completed its initial public offering (IPO), raising approximately $28.1 million in gross proceeds, which it plans to use to support its growth initiatives and product development. The IPO also facilitated the conversion of all outstanding convertible preferred stock into common stock, streamlining its capital structure.

As of June 30, 2025, CapsoVision reported a cash balance of $1.1 million and an accumulated deficit of $140.4 million. The company has expressed substantial doubt about its ability to continue as a going concern without additional capital. Despite the recent IPO, management anticipates that the net proceeds may not be sufficient to fund operations for the next 12 months, indicating a potential need for further financing to support ongoing operations and growth strategies.

Looking ahead, CapsoVision aims to expand its market share by increasing sales of its existing products and launching new offerings, including enhancements to its AI capabilities in the CapsoCam system. The company is also focused on penetrating the pediatric market and increasing telehealth adoption following recent FDA clearances. However, the company acknowledges that achieving these goals will require effective management of clinical development costs and successful navigation of regulatory processes.